U.S. Markets close in 4 hrs 28 mins


Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.0250.00 (0.00%)
As of 8:15AM CEST. Market open.
Full screen
Previous Close0.025
Bid0.000 x 5000000
Ask0.000 x 2800000
Day's Range0.025 - 0.025
52 Week Range0.002 - 0.061
Avg. Volume1,133
Market Cap5.36M
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • 3 Cheap Healthcare Stocks You Can Buy Right Now
    Motley Fool2 days ago

    3 Cheap Healthcare Stocks You Can Buy Right Now

    Amarin, Horizon Pharma, and Valeant Pharmaceuticals may be downright bargains right now. Here's why.

  • Horizon Pharma Gets Health Canada Approval for Procysbi
    Zacks8 days ago

    Horizon Pharma Gets Health Canada Approval for Procysbi

    Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.

  • Barrons.com12 days ago

    Valeant: Stop Looking in the Rearview Mirror!

    Shares of specialty pharmaceutical companies, including Valeant Pharmaceuticals International (VRX), Horizon Pharma (HZNP), Perrigo (PRGO), and Mallinckrodt (MNK), have been under pressure for a while now, as investors have remained focused on their business models of raising prices. In offering her upbeat view on specialty-pharmaceutical companies, Chen recommends investors to not "look back, because objects in the rearview mirror can appear closer than they are." In fact, she claims that management has already started to pivot from the old model of constantly rising prices, and the ones that can "innovate and/or save the healthcare system money can thrive under the new order." Chen initiated coverage on Aclaris Therapeutics (ACRS), Horizon Pharma, Impax Laboratories (IPXL), Mallinckrodt, Perrigo, Theravance Biopharma (TBPH), Valeant, Zoetis (ZTS), and Shire (SHPG), which she calls her "highest conviction recommendation.